Archive for November, 2008

Business Wire - Andrx’ Cardizem CD Launched in Canada

Thursday, November 27th, 2008

Business Editors/Health & Medical Writers
FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–March 12, 2001
Andrx Corporation — Andrx Group (Nasdaq:ADRX) today announced that Health Canada, the Canadian health authority, has approved the sale throughout Canada of all four strengths of its bioequivalent version of Cardizem(R) CD. Licensed to Rhoxalpharma, Inc., this product, marketed as Rhoxal-diltiazem CD, has already been launched. Diltiazem CD remains one of the largest selling pharmaceuticals i…

M2 Presswire - In- Depth Research on Biovail Corp.

Monday, November 24th, 2008

M2 PRESSWIRE-3 April 2007-Biotech News: In- Depth Research on Biovail Corp(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:03042007 In- Depth Research on Biovail Corp (NYSE:BVF) Biovail Corporation engages in the formulation, clinical testing, registration, manufacture, and commercializat…

M2 Presswire - Andrx claims exclusive generic marketing rights for Cardizem LA high blood pressure drug: TTMT, ONCY, ADRX, BVF, ABT.

Saturday, November 22nd, 2008

M2 PRESSWIRE-20 October 2005-SessionsIR.com: Andrx claims exclusive generic marketing rights for Cardizem LA high blood pressure drug: TTMT, ONCY, ADRX, BVF, ABT(C)1994-2005 M2 COMMUNICATIONS LTD RDATE:20102005 Stocks in the News: Tiger Team Technologies Incorporated (OTC: TTMT), Oncolytics Biotech Incorporated (NASDAQ: ONCY), Andrx Corporation (NASDAQ: ADRX), Biovail Corporation (NYSE: BVF), Abbott Laboratories Incorporated (NYSE: ABT) For Corporat…

Business Wire - Biovail Submits Cardizem LA NDA for Angina

Wednesday, November 19th, 2008

Business Editors/Health/Medical Writers
TORONTO–(BUSINESS WIRE)–July 2, 2003
Biovail Corporation (NYSE, TSX: BVF) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) fo…

Business Wire - Biovail Launches Cardizem LA to Physicians; Schedules Q1 Earnings Release for April 29, 2003

Saturday, November 15th, 2008

Business Editors/Health/Medical Writers
TORONTO–(BUSINESS WIRE)–April 2, 2003
Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that it has officially launched Cardizem(R) LA in the U.S. Launch elements include physician detailing, sampling, marketing and promotional activities. Biovail, in conjunction with the Company’s co-promotion partner Reliant Pharmaceuticals LLP, has approximately 800 sales representatives that…

Business Wire - Biovail Reports Positive CardizemLA Launch Results

Monday, November 10th, 2008

Business Editors/Health/Medical Writers
TORONTO–(BUSINESS WIRE)–April 29, 2003
— CardizemLA Prescriptions Exceed 20,000
— Retail Pharmacy Stocking Reaches 80%
— Managed Care Negotiations Cover 90% of U.S. Lives
Biovail Corporation (NYSE:BVF)(TSX:BVF) reported today on the progress of Cardizem(R)LA (diltiazem HCl), the recently launched once-daily controlled release medication for the treatment of hyperte…

Canadian Corporate News - Biovail Reports Positive CardizemLA Launch Results.

Saturday, November 8th, 2008

TORONTO, ONTARIO, Apr 29, 2003 (CCNMatthews via COMTEX)
— CardizemLA Prescriptions Exceed 20,000
— Retail Pharmacy Stocking Reaches 80%
— Managed Care Negotiations Cover 90% of U.S. Lives

Most Popular
The Art Of Public Speaking: Build Connection With Your Audience
10 Jobs That Pay $30 An Hour
Public S…

Canadian Corporate News - Biovail: Study Suggests Bedtime Dose Of Cardizem LA Protects Angina Patients From Morning Risks.

Tuesday, November 4th, 2008

CHICAGO, ILLINOIS, Mar 30, 2003 (CCNMatthews via COMTEX)
Presentation at American College of Cardiology Shows New Formulation Doubles Morning Exercise Tolerance, a Key Angina Measure
Nighttime dosing of a newly approved bl…